Home
>
National Drug Code (NDC)
>
Chlordiazepoxide Hydrochloride and Clidinium Bromide
Chlordiazepoxide Hydrochloride and Clidinium Bromide - 51293-607-10 - (Chlordiazepoxide Hydrochloride and Clidinium Bromide)
Drug Information of Chlordiazepoxide Hydrochloride and Clidinium Bromide
| Product NDC: | 51293-607 |
| Proprietary Name: | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Non Proprietary Name: | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Active Ingredient(s): | 5; 2.5 mg/1; mg/1 & nbsp; Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Chlordiazepoxide Hydrochloride and Clidinium Bromide
| Product NDC: | 51293-607 |
| Labeler Name: | ECI Pharmaceuticals LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | |
| Marketing Category: | UNAPPROVED DRUG OTHER |
| Start Marketing Date: | 20110504 |
Package Information of Chlordiazepoxide Hydrochloride and Clidinium Bromide
| Package NDC: | 51293-607-10 |
| Package Description: | 1000 CAPSULE in 1 BOTTLE (51293-607-10) |
NDC Information of Chlordiazepoxide Hydrochloride and Clidinium Bromide
| NDC Code | 51293-607-10 |
| Proprietary Name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Package Description | 1000 CAPSULE in 1 BOTTLE (51293-607-10) |
| Product NDC | 51293-607 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20110504 |
| Marketing Category Name | UNAPPROVED DRUG OTHER |
| Labeler Name | ECI Pharmaceuticals LLC |
| Substance Name | CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE |
| Strength Number | 5; 2.5 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Benzodiazepine [EPC],Benzodiazepines [Chemical/Ingredient],Anticholinergic [EPC],Decreased Parasympathetic Acetylcholine Activity [PE],GI Motility Alteration [PE],Digestive/GI System Activity Alteration [PE],Cholinergic Antagonists [MoA] |
